Insider · CIK 0001753143
Geoffrey B Pardo
Files at SI (SHOULDER INNOVATIONS, INC.), SGP (SpyGlass Pharma, Inc.). First filing Aug 5, 2025, latest Feb 11, 2026.
In brief
Geoffrey B Pardo files SEC Form 4 as director and 10% owner at SI (SHOULDER INNOVATIONS, INC.), and also at SGP (SpyGlass Pharma, Inc.). Since Aug 5, 2025, Geoffrey B Pardo has reported 2 open-market buys worth $6.5M and 0 open-market sells worth $0, the latest filed on Feb 11, 2026.
A track record needs three past buys with six months of prices behind them; Geoffrey B Pardo has 0, so none is measured yet.
The newest scored trade: bought $5.0M of SGP on Feb 9, 2026, filed Feb 11, 2026, scored 58 (moderate). In the last 12 months: 1 buy worth $5.0M and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
SGP: SpyGlass Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
SI: SHOULDER INNOVATIONS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | SpyGlass Pharma, Inc. | $5.0M 312,500 shares | +17% | - | |
| 65Notable | SHOULDER INNOVATIONS, INC. | $1.5M 100,000 shares | +4% | 0% from low-5% from high |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See footnote | +1,875,013 | $0.00 | $0 | 1,875,013 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | POpen-market purchase Common Stockindirect: See footnote | +312,500 | $16.00 | $5.0M | 2,187,513 | Feb 11, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series D Preferred Stockderivativeindirect: See footnote | -1,875,013 | - | - | 0 | Feb 11, 2026 |
| Feb 5, 2026 | SGP SpyGlass Pharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +27,400 | $0.00 | $0 | 27,400 | Feb 9, 2026 |
| Aug 1, 2025 | SI SHOULDER INNOVATIONS, INC. | CConversion Common Stockindirect: See Footnote | +2,280,482 | - | - | 2,280,482 | Aug 5, 2025 |
| Aug 1, 2025 | SI SHOULDER INNOVATIONS, INC. | POpen-market purchase Common Stockindirect: See Footnote | +100,000 | $15.00 | $1.5M | 2,380,482 | Aug 5, 2025 |
| Aug 1, 2025 | SI SHOULDER INNOVATIONS, INC. | AGrant or award Common Stock | +7,666 | $0.00 | $0 | 7,666 | Aug 5, 2025 |
| Aug 1, 2025 | SI SHOULDER INNOVATIONS, INC. | CConversion Series D Convertible Preferred Stockderivativeindirect: See Footnote | -33,259,424 | - | - | 0 | Aug 5, 2025 |
| Aug 1, 2025 | SI SHOULDER INNOVATIONS, INC. | CConversion Series E Convertible Preferred Stockderivativeindirect: See Footnote | -10,252,188 | - | - | 0 | Aug 5, 2025 |
Questions about Geoffrey B Pardo
Answered from the filings on this page, as of the latest one.
Is Geoffrey B Pardo buying or selling?
In the last 12 months Geoffrey B Pardo reported 1 open-market buy worth $5.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $5.0M of SGP on Feb 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Geoffrey B Pardo's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Geoffrey B Pardo has 0.
Where does Geoffrey B Pardo file Form 4?
Geoffrey B Pardo has filed Form 4 at SI (SHOULDER INNOVATIONS, INC.); SGP (SpyGlass Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.